Last SFr.270.10 CHF
Change Today -3.20 / -1.17%
Volume 1.4M
ROG On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 11:43 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Georg Nebgen Ph.D., MBA

Former Technology Project Leader, Roche Holding AG
AgeTotal Calculated CompensationThis person is connected to 11 board members in 3 different organizations across 13 different industries.

See Board Relationships
----

Background*

Dr. Georg Nebgen, Ph.D., MBA, was the Co-Founder and Managing General Partner at NGN Capital and NGN BioMed Opportunity I, L.P. Dr. Nebgen was the Principal and Managing Director of MPM Capital in Boston and Munich office. Dr. Nebgen also served as the Managing Director at MPM Capital GmbH. Previously he served as a Managed Care Area Manager for New England at Schering-Plough Corporation. Previously, Dr. Nebgen served in Schering-Plough's subsidiary in Switzerland as ...

Read Full Background

Corporate Headquarters*

Grenzacherstrasse 124
Basel, Basel-Stadt 4070

Switzerland

Phone: 41 61 688 11 11
Fax: 41 61 691 93 91

Board Members Memberships*

Director
Director
Former Director
Former Director
Former Director
Former Director
Former Director
Director
Former Chairman
Director
2004-2008
Former Director, Member of Nomination & Compensation Committee and Member of Financing Strategy & Transaction Committee
2005-Present
Director
2006-Present
Director

Education*

Doctorate
Rheinische Friedrich-Wilhelms-Universität Bonn
MBA
Universität St. Gallen

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROG:VX SFr.270.10 CHF -3.20

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€2.9M
Jeffrey R. Immelt Executive Chairman and Chief Executive Officer
General Electric Company
$8.5M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Richard A. Gonzalez Chairman, Chief Executive Officer and Chairman of Executive Committee
AbbVie Inc.
$1.5M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.